HEK293-PSMA Cells
USUSD$1,600.00*
Products are shipped frozen on dry ice in cryotubes. Each cryotube typically contains 3 × 106 cells for adherent lines or 5 × 106 cells for suspension lines (refer to the batch CoA for details).
一般資訊
| 說明 | Disclaimer: The prices displayed for cell lines are exclusively for academic/not-for-profit customers. For commercial entitites the price is approximately €6,250. HEK293-PSMA cells are human embryonic kidney 293 (HEK293) cells engineered to stably express human prostate-specific membrane antigen (PSMA), also known as glutamate carboxypeptidase II (FOLH1/GCPII). PSMA is a type II transmembrane glycoprotein with enzymatic folate hydrolase and carboxypeptidase activity that is highly expressed in prostate cancer, particularly in advanced, metastatic, and castration-resistant disease. In addition to prostate malignancies, PSMA expression has also been observed in the neovasculature of various solid tumors. Because of its strong tumor-associated expression and accessible extracellular domain, PSMA has become a major target for diagnostic imaging, radioligand therapy, antibody-based therapeutics, and engineered immune cell approaches. HEK293-PSMA cells are widely used in oncology research and therapeutic development for characterization of PSMA-targeted monoclonal antibodies, antibody-drug conjugates, radiopharmaceuticals, bispecific T-cell engagers, CAR-T cell therapies, and small-molecule inhibitors. The stable recombinant expression system enables quantitative analysis of ligand binding, receptor occupancy, antigen density, internalization kinetics, and target-dependent cytotoxicity. These cells are particularly valuable for evaluating PSMA-directed imaging probes and radioligand platforms, as PSMA undergoes efficient internalization following ligand engagement. Additional applications include flow cytometry assay development, uptake studies, reporter assays, high-throughput screening, and validation of targeted delivery systems for prostate cancer therapeutics. |
|---|---|
| 生物體 | Human |
| 組織 | Fetal Kidney |
| 疾病 | Transformed/immortalized; non-tumorigenic (HEK293 background) |
| 應用 | PSMA-targeted antibody, ADC and radiopharmaceutical development; prostate cancer therapeutics; CAR-T cell therapy; ADCC/CDC assays; flow cytometry; prostate cancer research |
特徵
| 年齡 | Fetus |
|---|---|
| 性別 | Female |
| 形態學 | Epithelial-like |
| 細胞類型 | Epithelial cells |
| 生長特性 | Monolayer, adherent |
監管數據
| 引用 | HEK293-PSMA (Cytion catalog number 305992) |
|---|---|
| 生物安全等級 | 1 |
| NCBI_TaxID | 9606 |
| Cellosaurus 編號 | CVCL_6G28 |
| 轉基因狀態 | GMO-S1: This HEK293 cell line contains a PSMA (FOLH1) expression construct for prostate-specific membrane antigen studies and targeted therapy development. This classification applies only within Germany and may differ elsewhere. |
生物分子資料
| 受體的表達 | PSMA |
|---|
處理方式
| 培養基 | RPMI 1640, w: 2.0 mM stable Glutamine, w: 2.0 g/L NaHCO3 (Cytion article number 820700a) |
|---|---|
| 營養補充品 | Supplement the medium with 10% FBS, 1 mM sodium pyruvate, 10 mM HEPES, 1% NEAA. Add Geneticin (G418-Sulfat) to achieve a final concentration of 1 mg/mL. |
| 解離試劑 | Trypsin-EDTA |
| 倍增時間 | approx. 24-36 hours |
| 傳代培養 | For routine adherent cell culture: Aspirate the old culture medium from the adherent cells, and wash them with PBS to remove any remaining medium. After aspirating the PBS, add the appropriate volume of Trypsin/EDTA solution based on the culture vessel size (e.g., 1 ml for a T25 flask, 3 ml for a T75 flask) and incubate at room temperature or 37°C until the cells detach (5-10 minutes). Monitor detachment under a microscope, and gently tap the vessel if necessary to release the cells. Once detached, add complete medium to inactivate the Trypsin/EDTA, gently resuspend the cells, and transfer an aliquot of the cell suspension into a new culture vessel containing fresh medium. Place the vessel in an incubator set to 37°C with 5% CO2, and change the medium every 2-3 days. |
| 拆股比例 | 1 to 5 |
| 播種密度 | 2 to 4 x 104 cells/cm2 |
| 流體更新 | 2 to 3 times per week |
| 解凍後的恢復 | After thawing, split the cells at a ratio of 1:2 to 1:3 in T25 flasks and allow the cells to recover from the freezing process and to adhere for at least 24 hours. For best attachment and viability after thawing the cells, we recommend using Collagen-coated flasks or plates for the initial seeding after cryo-recovery. Collagen coating is not required for subsequent routine culture of the cells. |
| 冷凍培養基 | As a cryopreservation medium, we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability, or CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. |
| 細胞解凍與培養 |
|
| 培養環境 | 37°C, 5% CO2, humidified atmosphere. |
| 運送條款 | Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage. |
| 儲存條件 | For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen. |
品質控制與分子分析
| 不孕症 | Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods. To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections. |
|---|